Project description
Assessing an innovative treatment of PCOS in young patients
As the most frequent cause of anovulatory subfertility, polycystic ovary syndrome (PCOS) affects a significant percentage of adolescents and young women worldwide. In a landscape that lacks effective therapies, pilot studies have led to the development of a novel medication focused on the reversion of the PCOS phenotype without side effects through a single tablet called SPIOMET. The EU-funded SPIOMET4HEALTH project aims at evaluating this innovative approach focusing on the additive effects of SPIOMET's components. The project aspires to provide the first large-scale evidence on the psychosocial benefits of the tested treatments and to contribute to solid decision-making about PCOS across European healthcare systems.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation action
Coordinator
08950 Esplugues De Llobregat
Spain
See on map
Participants (19)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
08950 Esplugues De Llobregat
See on map
3000 Leuven
See on map
17190 Girona
See on map
58455 Witten
See on map
8010 Graz
See on map
7100 Vejle
See on map
7491 Trondheim
See on map
40126 Bologna
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
40138 Bologna
See on map
34452 Istanbul
See on map
07121 Palma De Mallorca
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
08970 Sant Joan Despi
See on map
28040 Madrid
See on map
12006 Castellón De La Plana
See on map
2 Dublin
See on map
1040 Bruxelles
See on map
08014 Barcelona
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
08012 Barcelona
31192 Mutilva Alta Navarra
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.